Gilead's stock is rated a "buy" due to its thriving HIV business, promising oncology pipeline, and potential for long-term growth despite some volatility. The company's Q3 earnings show strong ...

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological ...

Polaris Global Equity Strategy highlighted stocks like Gilead Sciences, Inc. (NASDAQ:GILD), in the third quarter 2024 investor letter. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical ...

For 14 years, scientists have been growing a tree akin to the Judean balsam — the source of the balm of Gilead — but with no modern counterpart. For 14 years, scientists have been growing a ...

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase its ownership in the antiviral developer to 29.9% following an equity ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January, alarming community activists who worry the move will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences (GILD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Looking at the universe of stocks we cover at Dividend Channel, on 12/13/24, Thermo Fisher Scientific Inc (Symbol: TMO), Gilead Sciences Inc (Symbol: GILD), and National Storage Affiliates Trust ...

Through this agreement, Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to utilize, with Tubulis ...